Health
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1
About this update from Nuvation Bio Inc.
[{"type":"text","content":"Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases","length":157,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, April 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) patients with brain metastases.","length":625,"tagName":"p"},{"type":"image","alt":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","displaySize":"","headline":null,"caption":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":67,"url":"https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VSdvqELO80DAUOQ0oaqyVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExOA--/https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988","width":400,"height":67}},"href":"https://mma.prnewswire.com/media/2924210/Nuvation_Bio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The NCCN previously added taletrectinib (IBTROZI) as a Preferred Agent for both first-line and subsequent therapy for ROS1+ NSCLC in its Clinical Practice Guidelines in Oncology for NSCLC in June 2025, after its approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Taletrectinib (IBTROZI) is a highly selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to address some of the outstanding challenges of treating the disease. Taletrectinib (IBTROZI) has demonstrated efficacy in patients with brain metastases with a 76.5% intracranial overall response rate in TKI-naive patients and a 65.6% intracranial response rate among TKI-pretreated patients, as recently presented at the American...